Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics analysis of the molecular mechanism by which Antibody-drug conjugate Oba01 combined with Abemaciclib kills colorectal cancer organoids

ABSTRACT: Proteomics reveals the molecular mechanism by which the antibody-drug conjugate Oba01 and the CDK4/6 inhibitor Abemaciclib jointly kill colorectal cancer organoids

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Dr Shuyong Zhang

PROVIDER: PXD063571 | JPOST Repository | Sat May 03 00:00:00 GMT+01:00 2025

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Match_result.zip	Other
	PDXO_Proteomics.xlsx	Xlsx
	Raw_file.zip	Other

Items per page:

1 - 3 of 3

Similar Datasets

Proteomics analysis of the molecular mechanism by which Oba01 combined with Abemaciclib kills colorectal cancer organoids

Project description:Proteomics reveals the molecular mechanism by which the antibody-drug conjugate Oba01 and the CDK4/6 inhibitor Abemaciclib jointly kill colorectal cancer organoids

2025-05-01 | PXD063685 |

Metabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS

Project description:As metabolic rewiring is crucial for cancer cell proliferation, metabolic phenotyping of patient-derived organoids is desirable to identify drug-induced changes and trace metabolic vulnerabilities of tumor subtypes. We established a novel protocol for metabolomic and lipidomic profiling of colorectal cancer organoids by LC-QTOF-MS facing the challenge of capturing metabolic information from minimal sample amount (< 500 cells/injection) in the presence of extracellular matrix (ECM). The best procedure of the tested protocols included ultrasonic metabolite extraction with acetonitrile/methanol/water (2:2:1, v/v/v) without ECM removal. To eliminate ECM-derived background signals, we implemented a data filtering procedure based on p-value and fold change cut-offs which retained features with signal intensities >120% compared to matrix-derived signals present in blank samples. As a proof-of-concept, the method was applied to examine the early metabolic response of colorectal cancer organoids to 5-fluorouracil treatment. Statistical analysis revealed dose-dependent changes in the metabolic profiles of treated organoids including elevated levels of 2'-deoxyuridine, 2'-O-methylcytidin, inosine and 1-methyladenosine and depletion of 2'-deoxyadenosine and specific phospholipids. In accordance with the mechanism of action of 5-fluorouracil, changed metabolites are mainly involved in purine and pyrimidine metabolism. The novel protocol provides a first basis for the assessment of metabolic drug response phenotypes in 3D organoid models.

2021-10-12 | MTBLS2130 | MetaboLights

DIA analysis of colorectal cancer organoids

Project description:The goal of this project was to characterize the proteome and phosphoproteome of colorectal cancer organoids.

2023-12-10 | PXD018913 | Pride

DIA analysis of colorectal cancer organoids

Project description:The goal of this project was to characterize the proteome of colorectal cancer organoids from different patients.

2023-11-16 | PXD019124 | Pride

RNAseq of colorectal cancer organoids

Project description:RNAseq of colorectal cancer organoids

| PRJNA904315 | ENA

Building a spectral library to analyze colorectal cancer organoids

Project description:The goal of this project was to build SWATH Spectral libraries to analyze colorectal cancer organoids.

2023-12-10 | PXD018835 | Pride

DIA analysis of colorectal cancer organoids (cancer vs metastasis)

Project description:The goal of this project was to characterize the proteome of colorectal cancer organoids from a metastatic and original tumor.

2023-12-10 | PXD018922 | Pride

Building spectral libraries to analyze phosphopeptides in colorectal cancer organoids

Project description:The goal of this project was to build SWATH Spectral libraries to analyze phosphopeptides from colorectal cancer organoids.

2023-12-10 | PXD018862 | Pride

Expression data of cultured organoids derived from human colorectal cancer.

Project description:We analyzed gene expression of 3 lines of patient-derived colorectal cancer organoids.

2022-01-05 | GSE184732 | GEO

Effects of Simulated Microgravity on Colorectal Cancer Organoids Growth and Drug Response

Project description:Cellular and molecular dynamics of human cells are constantly affected by gravity. Alteration of the gravitational force disturbs the cellular equilibrium, which might modify physiological and molecular characteristics. Nevertheless, biological responses of cancer cells to reduced gravitational force remains obscure. Here, we aimed to comprehend not only transcriptomic patterns but drug responses of colorectal cancer (CRC) under simulated microgravity. We established four organoids directly from CRC patients, and organoids cultured in 3D clinostat were subjected to genome wide expression profiling and drug library screening. Our observations revealed changes in cell morphology and an increase in cell viability under simulated microgravity compared to their static controls. Transcriptomic analysis highlighted a significant dysregulation in the TBC1D3 family of genes. The upregulation of cell proliferation observed under simulated microgravity conditions was further supported by enriched cell cycle processes, as evidenced by the functional clustering of mRNA expressions using cancer hallmark and gene ontology terms. Our drug screening results indicated an enhanced response rate to 5-FU under conditions of simulated microgravity, suggesting potential implications for cancer treatment strategies in simulated microgravity.

2024-09-11 | GSE271642 | GEO